Literature DB >> 10495131

Dynamics of skeletal resistance to parathyroid hormone in the rat: effect of renal failure and dietary phosphorus.

J Bover1, A Jara, P Trinidad, M Rodriguez, A J Felsenfeld.   

Abstract

UNLABELLED: Secondary hyperparathyroidism develops in renal failure and is generally ascribed to factors directly affecting parathyroid hormone (PTH) production and/or secretion. These include hypocalcemia, phosphorus retention, and a calcitriol deficiency. However, not often emphasized is that skeletal resistance to PTH is an important factor. Our study evaluated: (1) the relative effects of uremia and dietary phosphorus on the skeletal resistance to PTH; and (2) how, during a PTH infusion, the dynamics of skeletal resistance to PTH were affected by renal failure. Renal failure was surgically induced and, based on serum creatinine, rats were divided into normal, moderate renal failure, and advanced renal failure. In each group, three diets with the same calcium (0.6%) but different phosphorus contents were used: high (1.2%, HPD); moderate (0.6%, MPD); and low (0.2%, LPD) phosphorus. The study diet was given for 14-16 days followed by a 48 h infusion of rat PTH(1-34) (0.11 microg/100 g per hour), a dose five times greater than the normal replacement dose. During the PTH infusion, rats received a calcium-free, low phosphorus (0.2%) diet. In both moderate and advanced renal failure, the PTH level was greatest in the HPD group (p < 0.05) and, despite normal serum calcium values, PTH was greater in the MPD than the LPD group (p < 0.05). Despite phosphorus restriction and normal serum calcium and calcitriol levels in the azotemic LPD groups, the PTH level was greater (p < 0.05) in the LPD group with advanced rather than moderate renal failure. During PTH infusion, the increase in serum calcium was progressively less (p < 0.05) in all groups as renal function declined. Furthermore, despite normal and similar serum phosphorus values at the end of PTH infusion, the serum calcium concentration was less (p < 0.05) in the HPD group than the other two groups and similar in the LPD and MPD groups. IN
CONCLUSION: (1) uremia and phosphorus each had separate and major effects on skeletal resistance to PTH; (2) skeletal resistance to PTH was an important cause of secondary hyperparathyroidism, even in moderate renal failure; (3) during PTH infusion, the dynamics of skeletal resistance to PTH changed because all groups received a low phosphorus diet, and the adaptation to a new steady state was delayed by the degree of renal failure and the previous dietary phosphorus burden; and (4) normal serum phosphorus may not be indicative of body phosphorus stores during states of disequilibrium.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10495131     DOI: 10.1016/s8756-3282(99)00169-6

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  10 in total

Review 1.  Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.

Authors:  Ziad Massy; Tilman Drueke
Journal:  J Nephrol       Date:  2017-04-12       Impact factor: 3.902

Review 2.  The Non-invasive Diagnosis of Bone Disorders in CKD.

Authors:  Jordi Bover; Pablo Ureña-Torres; Mario Cozzolino; Minerva Rodríguez-García; Carlos Gómez-Alonso
Journal:  Calcif Tissue Int       Date:  2021-01-04       Impact factor: 4.333

3.  Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients.

Authors:  Konstantinos K Doumouchtsis; Alkis I Kostakis; Stergios K Doumouchtsis; Marios P Tziamalis; Charalambos P Stathakis; Evanthia Diamanti-Kandarakis; Dimitrios Dimitroulis; Despoina N Perrea
Journal:  J Bone Miner Metab       Date:  2008-01-10       Impact factor: 2.626

4.  Effects of dietary phosphates from organic and inorganic sources on parameters of phosphorus homeostasis in healthy adult dogs.

Authors:  Britta Dobenecker; Sven Reese; Sarah Herbst
Journal:  PLoS One       Date:  2021-02-19       Impact factor: 3.240

5.  The disparity of measuring bone mineral content using bioimpedance and dual-energy absorptiometry in the context of hyperparathyroidism.

Authors:  Shirley Ferraz Crispilho; Eduardo Jorge Duque; Kalyanna Soares Bezerra; Rosa Maria R Pereira; Vanda Jorgetti; Rosilene M Elias; Rosa M A Moysés
Journal:  J Bras Nefrol       Date:  2021 Apr-Jun

6.  Benefits of omega-3 fatty acid against bone changes in salt-loaded rats: possible role of kidney.

Authors:  Mona A Ahmed; Abeer A Abd El Samad
Journal:  Physiol Rep       Date:  2013-09-23

Review 7.  Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence.

Authors:  M Jesús Lloret; César Ruiz-García; Iara Dasilva; Mónica Furlano; Yaima Barreiro; José Ballarín; Jordi Bover
Journal:  Patient Prefer Adherence       Date:  2013-11-06       Impact factor: 2.711

Review 8.  Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation.

Authors:  Jordi Bover; Mario Cozzolino
Journal:  Kidney Int Suppl (2011)       Date:  2011-09

9.  Association of Anabolic Effect of Calcitriol with Osteoclast-Derived Wnt 10b Secretion.

Authors:  Chien-Lin Lu; Jia-Fwu Shyu; Chia-Chao Wu; Chi-Feng Hung; Min-Tser Liao; Wen-Chih Liu; Cai-Mei Zheng; Yi-Chou Hou; Yuh-Feng Lin; Kuo-Cheng Lu
Journal:  Nutrients       Date:  2018-08-25       Impact factor: 5.717

10.  The Source Matters-Effects of High Phosphate Intake from Eight Different Sources in Dogs.

Authors:  Britta Dobenecker; Ellen Kienzle; Stephanie Siedler
Journal:  Animals (Basel)       Date:  2021-12-04       Impact factor: 2.752

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.